Picture loading failed.

Anti-ERBB2 therapeutic antibody (Pre-made Pertuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-439-1mg 1mg 3090
GMP-Bios-ab-439-10mg 10mg 21890
GMP-Bios-ab-439-100mg 100mg 148000
GMP-Bios-ab-439-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ERBB2 therapeutic antibody (Pre-made Pertuzumab biosimilar,Whole mAb)
INN Name Pertuzumab
TargetERBB2
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure1l7i:HL/4llu:AB:CD/1s78:FE:DC
99% SI StructureNone
95-98% SI Structure4lly:AB:CD/4llw:CD:AB/5vsh:CD:AB:EF:HL
Year Proposed2003
Year Recommended2004
CompaniesChugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group
Conditions ApprovedBreast cancer
Conditions ActiveOvarian cancer;Brain metastases;Colorectal cancer
Conditions DiscontinuedGastric cancer;Non-small cell lung cancer;Prostate cancer
Development Techna